Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.
about
Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Safety and Immunogenicity of N ...... 2 Randomized Controlled Trial.
@en
Safety and Immunogenicity of N ...... 2 Randomized Controlled Trial.
@nl
type
label
Safety and Immunogenicity of N ...... 2 Randomized Controlled Trial.
@en
Safety and Immunogenicity of N ...... 2 Randomized Controlled Trial.
@nl
altLabel
Safety and Immunogenicity of N ...... 2 Randomized, Controlled Trial
@en
prefLabel
Safety and Immunogenicity of N ...... 2 Randomized Controlled Trial.
@en
Safety and Immunogenicity of N ...... 2 Randomized Controlled Trial.
@nl
P2093
P2860
P50
P356
P1476
Safety and Immunogenicity of N ...... 2 Randomized Controlled Trial.
@en
P2093
Anneke C Hesseling
Danelle Van As
Elisa Nemes
Gerhard Walzl
Humphrey Mulenga
Katrina Downing
Katya Mauff
MVA029 Study Team
Marieke van der Zalm
Michele Tameris
P2860
P304
P356
10.1093/CID/CIX834
P407
P577
2017-09-26T00:00:00Z